Ret On Web

Solar maculopathy      Usually this condition is seen after direct exposure to solar eclipse, or long duration of sun viewing in snow, or with excess heat.    Patients will have complains of minimal blurring of vision or distortion of vision.  On examination, most of the times VA will be better than 6/9. Fundus evaluation shows enhanced red reflex with lamellar hole like picture. OCT shows loss of IS-OS junction over foveolar area.  Pathogenesis is said that sudden exposure to UV rays will cause burn of retina in that small area. There is no treatment for this condition, so prevention of direct exposure to eclipse is advised. 

PREGNANCY and EYE During pregnancy,  progressive physiological changes that occur are essential to support and protect the developing fetus in addition to prepare the mother for parturition. These changes can lead to few ocular complications. In general, the ocular effect of pregnancy can be divided in to physiologic and pathologic changes. The pathologic changes are further divided in to the following: Ocular changes occurring for the first time during pregnancy An already existing ocular pathology that is modified by pregnancy Ocular complications of systemic diseases. Physiologic Changes Eyelids Increased pigmentations around the eye called as melasma or chloasma Postulated that hormonal variations of pregnancy increase melanin as a result of an increase in both melanogenesis and melanocytosis Tear Pregnancy affects the physiology of the tear film resulting in dry eye syndrome. Cornea Cornea may show changes in sensitivity, thickness or curvature.

Can progression of geographic atrophy( GA) in Dry AMD be prevented?? As we know, there are more than 5 million people affected with GA, with high chance of 35 to 50 % development of GA in other whom there is advanced GA in one eye.    Currently the antiVEGF what we have can lead to increase in progresion of GA than to prevent it. Recently ,  Lampalizumab (Genentech) is an antigen-binding fragment of a humanized monoclonal antibody directed against complement factor D has been currently being evaluated in two identical phase 3 trials in patients with GA: Spectri (NCT02247531) and Chroma (NCT02247479). So in future we may have treatment for prevention of progression of GA in high risk people